Skip to main content
Premium Trial:

Request an Annual Quote

UC, San Diego Selected as Site for Benitec HCV Drug Trial

Premium

Benitec Biopharma this week announced that the University of California, San Diego, has been selected as another site of the company’s phase I/II trial of the expressed RNAi-based hepatitis C treatment TT-034.

Last month, the company said that the Duke Clinical Research Unit would also be a site for the trial (GSN 3/28/2013).

The trial is designed to evaluate single escalating doses of the drug in patients with chronic HCV genotype I infection who have failed previous treatment, Benitec said.

It is expected to enroll 14 patients in five sequential dose cohorts, with the possibility of additional cohorts to confirm study findings. Endpoints include safety, as well as serum viral load reduction and hepatocyte transduction levels.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.